AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03521895
Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
RxNorm normalized name: Eylea
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients observed with regular and irregular treatment course
Trial: NCT02299401
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women will receive three 800 mcg doses of misoprostol.
Trial: NCT02802670
Drug: [14C]-GDC-0810
DrugBank: GDC-0810 (DB12253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single 300-mg dose of GDC-0810 containing approximately 100 microcuries of \[14C\]-labeled GDC-0810 on Day 1.
Trial: NCT03920722
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
Trial: NCT01280201
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single arm of pazopanib 800 mg (2x400mg) given once daily as a single agent.
Trial: NCT01331018
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01331018
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT01331018
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00274924
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03666299
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion of 2% lidocaine hydrochloride at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
Trial: NCT03666299
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion of normal saline at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
Trial: NCT03535506
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib capsules for oral administration contain 125 mg, 100 mg, or 75 mg of palbociclib, a kinase inhibitor.
Trial: NCT00274924
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00274924
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00274924
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken orally
Trial: NCT00274924
Drug: vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01393548
Drug: brompheniramine + phenylephrine
RxNorm normalized name: brompheniramine / phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution: brompheniramine (2mg/mL) and phenylephrine (2,5 mg/mL), t.i.d., according weight of patient.~OR Syrup: brompheniramine (2mg/5mL) and phenylephrine(5 mg/5mL), t.i.d., according weight of patient.
Trial: NCT01393548
Drug: Brompheniramine + pseudoephedrine
RxNorm normalized name: brompheniramine / pseudoephedrine
DrugBank: Brompheniramine (DB00835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elixir: Brompheniramine (0,2mg/mL) and pseudoephedrine (3,0 mg/mL), t.i.d., according weight of patient
Trial: NCT01844869
Drug: omacetaxine mepesuccinate
RxNorm normalized name: Omacetaxine Mepesuccinate
DrugBank: Omacetaxine mepesuccinate (DB04865)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05151796
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily aspirin intake for cardiovascular prevention
Trial: NCT03412994
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib in combination with standard second-line chemotherapy for advanced colorectal cancer
Trial: NCT04331418
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mcg/kg IV over 10 minutes followed by 0.5 mcg/kg/hr
Trial: NCT00533585
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg/m\^2 By Vein Over 3 Hours on Day 1.
Trial: NCT00533585
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Area under curve (AUC) 6 By Vein Over 30 Minutes on Day 1.
Trial: NCT00533585
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting Dose of 5 mg/kg By Vein Over 90 minutes on Day 1.
Trial: NCT00203931
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00203931
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01696227
Drug: Nissle 1917
RxNorm normalized name: escherichia coli, strain Nissle 1917, live
DrugBank: Escherichia coli strain Nissle 1917 (DB16603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uropathogens will be challenged to share the same in vitro environment with Nissle 1917.
Trial: NCT02967380
Drug: Gadobenate Dimeglumine
RxNorm normalized name: Gadobenate Dimeglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02967380
Drug: Gadobutrol
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04676971
Drug: Placebo (Normal saline solution)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7, D14(if necessary)
Trial: NCT02169180
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response \[CR\]), unacceptable toxicity, or end of treatment, whichever occurs first.
Trial: NCT02536755
Drug: Eliglustat, GZ385660
DrugBank: Eliglustat (DB09039)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Trial: NCT01057160
Drug: Rizatriptan
RxNorm normalized name: Rizatriptan
DrugBank: Rizatriptan (DB00953)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic
Trial: NCT03102190
Drug: Verapamil Hydrochloride Intranasal
RxNorm normalized name: Verapamil Hydrochloride
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil solution for injection, supplied in vials, will be utilized in a Neil Med Sinus Rinse of 240mL buffered normal saline.
Trial: NCT01609478
Drug: indacaterol
RxNorm normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler
Trial: NCT01609478
Drug: mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: via Twisthaler inhaler
Trial: NCT01872858
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin, 100mg, Q.D, p.o, 2yr
Trial: NCT01872858
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cilostazol, 100mg, B.I.D, p.o, 2yr
Trial: NCT02426125
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT02426125
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT00960687
Drug: Fenofibric Acid (Fibricor™) 105 mg Tablet
RxNorm normalized name: fenofibric acid 105 MG [Fibricor]
DrugBank: Fenofibric acid (DB13873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 105 mg fenofibric acid (Fibricor™) tablet administered 30 minutes after the initiation of a standard breakfast.
Trial: NCT00960687
Drug: Fenofibrate (Tricor®) 145 mg Tablet
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 145 mg Fenofibrate (Tricor®) tablet administered 30 minutes after the start of a standard breakfast.
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/vilanterol
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umeclidinium/vilanterol
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclometasone dipropionate/formoterol
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide formoterol
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umeclidinium
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol glycopyrronium
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium olodaterol
Trial: NCT01067443
Drug: Liposomal amphotericin B (AmBisome®) and sodium stibogluconate
RxNorm normalized name: amphotericin B liposomal Injection [AmBisome]
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
Trial: NCT01067443
Drug: Liposomal amphotericin B + miltefosine
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium/formoterol
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olodaterol
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol/glycopyrronium bromide/beclometasone dipropionate
Trial: NCT03662711
Drug: Bronchodilator Agents
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/umeclidinium bromide/vilanterol
Trial: NCT00000282
Drug: Pemoline
RxNorm normalized name: Pemoline
DrugBank: Pemoline (DB01230)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00141479
Drug: Bifeprunox
RxNorm normalized name: Bifeprunox
DrugBank: Bifeprunox (DB04888)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02058368
Drug: Dutasteride 0.5mg capsules
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
Trial: NCT02058368
Drug: Dutasteride placebo capsules
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
Trial: NCT02058368
Drug: Tamsulosin 0.2mg tablets
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available tamsulosin 0.2mg tablets will be supplied.
Trial: NCT00143546
Drug: Defibrotide
RxNorm normalized name: Defibrotide
DrugBank: Defibrotide (DB04932)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Defibrotide to be administered approximately every 6 hours at an initial dose of 6.25 mg/kg/dose. Subsequent doses will be escalated with a plateau of 15 mg/kg/dose (or 60 mg/kg/day total). For patients with persistent VOD, the dose may be escalated by 10 mg/kg/day as needed to a maximum of 110 mg/kg/day total.
Trial: NCT01067443
Drug: Miltefosine
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
Trial: NCT00235001
Drug: trandolapril/verapamil
RxNorm normalized name: TRANDOLAPRIL/VERAPAMIL
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180/2 mg QD
Trial: NCT02112045
Drug: Granix
RxNorm normalized name: Granix
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02112045
Drug: High dose melphalan (HDR)
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04308889
Drug: Lovaza
RxNorm normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovaza contains ethyl esters of omega-3 fatty acids (EPA and DHA) obtained from the oil of several fish sources.
Trial: NCT00445588
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg Given orally once daily
Trial: NCT00445588
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg Given orally twice daily
Trial: NCT02578368
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2600 mg/m², d1 i.v., every 2 weeks
Trial: NCT02578368
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m², d1, i.v., every 2 weeks
Trial: NCT02578368
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg/m², d1, i.v., every 2 weeks
Trial: NCT02578368
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 mg/kg BW (6 mg loading dose at 1st administration), i.v. for 1 h, d1, i.v., every two weeks
Trial: NCT02578368
Drug: sodium folinate
RxNorm normalized name: Sodium folinate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: can be used to replace leucovorin (calcium folinate)
Trial: NCT03907540
Drug: Belumosudil 200 mg tablet
RxNorm normalized name: belumosudil
DrugBank: Belumosudil (DB16703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belumosudil 200 mg tablet, development candidate
Trial: NCT02057328
Drug: TELMISARTAN
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients of the group of telmisartan will take 40 mg of telmisartan daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients still classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
Trial: NCT02057328
Drug: NEBIVOLOL
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. For patients classified in the stage I hypertensive range 12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project
Trial: NCT03608761
Drug: Rebamipide
RxNorm normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: rebamipide 2%
Trial: NCT00134420
Drug: Nutropin AQ
RxNorm normalized name: Nutropin AQ
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (Nutropin AQ) treatment given to Group 1 immediately Growth Hormone (Nutropin AQ) treatment given to Group 2 after one year observation
Trial: NCT02181842
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone tablets
Trial: NCT03681275
Drug: Tofacitinib 10 MG [Xeljanz]
RxNorm normalized name: tofacitinib 10 MG [Xeljanz]
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administered twice daily for two days
Trial: NCT03771768
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 \&5gm paste 4 times/day
Trial: NCT01044329
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal, 1.25 mg, 3 times, one month apart.
Trial: NCT01044329
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal, 2 mg, 2 times, two months apart.
Trial: NCT01863589
Drug: Adefovir tablets
DrugBank: Adefovir (DB13868)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to the prescribing information in the locally approved label by the authorities.
Trial: NCT00938886
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily 50 mg naltrexone
Trial: NCT02591771
Drug: adrenaline
RxNorm normalized name: Adrenaline
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
Trial: NCT01247805
Drug: sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of 1 x 20 mg IR oral tablet.
Trial: NCT01247805
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single oral dose of 2 x 10 mg sildenafil citrate IR oral tablet.
Trial: NCT01247805
Drug: sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single oral dose of 2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).